Stock Analysis on Net
Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Analysis of Liquidity Ratios
Quarterly Data

Beginner level


Liquidity Ratios (Summary)

Johnson & Johnson, liquidity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Current ratio 1.25 1.31 1.26 1.26 1.33 1.44 1.47 1.72 1.65 1.58 1.41 1.32 1.34 2.52 2.47 2.73 3.08 2.83 2.17 2.51 2.49 2.44
Quick ratio 0.92 0.98 0.94 0.93 0.95 1.01 1.08 1.22 1.17 1.08 1.04 0.92 0.91 2.06 2.04 2.25 2.54 2.32 1.77 1.93 1.87 1.80
Cash ratio 0.52 0.54 0.54 0.51 0.49 0.53 0.63 0.71 0.66 0.56 0.60 0.51 0.45 1.57 1.59 1.74 1.98 1.80 1.38 1.48 1.39 1.31

Based on: 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Johnson & Johnson’s current ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Johnson & Johnson’s quick ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Johnson & Johnson’s cash ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Current Ratio

Johnson & Johnson, current ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Current assets 45,892  44,226  45,274  44,333  41,799  41,987  46,033  47,194  45,438  42,768  43,088  41,829  38,789  63,347  65,032  63,319  66,291  62,738  60,210  63,494  61,001  58,192 
Current liabilities 36,772  33,689  35,964  35,162  31,353  29,111  31,230  27,437  27,488  27,081  30,537  31,806  28,872  25,119  26,287  23,230  21,536  22,134  27,747  25,260  24,512  23,836 
Liquidity Ratio
Current ratio1 1.25 1.31 1.26 1.26 1.33 1.44 1.47 1.72 1.65 1.58 1.41 1.32 1.34 2.52 2.47 2.73 3.08 2.83 2.17 2.51 2.49 2.44
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.57 1.43 1.44 1.54 1.68 1.58 1.62 1.42 1.58 1.66 2.26 2.69 2.94 2.91 4.02 1.56 1.50 1.48 1.54 1.82 2.30 2.17
AbbVie Inc. 0.86 3.14 3.18 1.15 0.89 1.04 0.98 1.20 0.80 1.20 1.28 1.45 1.38 1.76 1.65 1.79 1.81 1.56 1.50 2.03 1.50 1.39
Amgen Inc. 2.18 1.59 1.44 2.89 2.89 2.77 2.79 3.08 3.39 3.88 5.49 6.07 6.20 4.41 4.11 4.35 3.97 4.95 4.44 5.42 5.48 5.53
Biogen Inc. 2.46 1.73 1.72 1.91 2.46 2.84 2.32 2.75 2.36 3.23 2.34 2.19 2.10 2.29 2.55 3.24 2.96 2.59 2.60 3.52 2.20 2.70
Bristol-Myers Squibb Co. 1.47 1.66 1.60 3.83 3.88 1.93 1.61 1.53 1.40 1.52 1.55 1.59 1.59 1.60 1.55 1.47 1.56 1.48 1.30 1.81 1.76 1.94
Eli Lilly & Co. 1.22 1.11 1.16 1.17 1.13 1.12 1.73 1.91 1.40 1.41 1.32 1.38 1.39 1.24 1.37 1.62 1.54 1.60 1.53 1.51 1.50 1.41
Gilead Sciences Inc. 2.33 3.04 3.10 2.96 3.76 3.62 3.38 3.45 3.00 2.84 2.74 3.68 3.37 2.59 2.22 1.93 1.76 1.77 2.50 2.77 2.03 2.70
Illumina Inc. 3.76 4.10 6.69 6.82 6.79 3.66 2.49 2.46 2.74 2.71 3.99 4.22 3.88 3.49 3.29 3.62 3.69 4.31 3.43 3.79 3.09 2.90
Merck & Co. Inc. 1.32 1.11 1.24 1.26 1.21 1.37 1.17 1.44 1.33 1.42 1.33 1.43 1.50 1.59 1.78 1.89 1.87 1.64 1.55 1.62 1.62 1.61
Pfizer Inc. 1.42 1.03 0.88 0.90 1.47 1.54 1.57 1.43 1.16 1.27 1.35 1.43 1.34 1.44 1.25 1.11 1.37 1.44 1.49 1.62 2.14 2.45
Regeneron Pharmaceuticals Inc. 2.12 4.21 3.67 4.03 3.88 4.58 4.47 4.04 3.62 3.59 3.82 3.63 3.75 2.80 2.56 3.64 3.37 3.41 3.59 3.64 3.80 4.31
Vertex Pharmaceuticals Inc. 3.72 3.54 3.61 3.44 3.74 3.78 3.43 3.71 3.67 3.68 3.28 3.28 3.49 3.82 2.31 2.08 2.33 2.54 2.78 3.63 3.46 4.49
Zoetis Inc. 3.47 2.77 2.63 4.39 4.17 4.05 3.60 4.06 4.38 4.27 3.85 2.80 2.01 1.96 3.03 3.24 3.20 2.84 2.15 2.08 2.11 2.27

Based on: 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q2 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= 45,892 ÷ 36,772 = 1.25

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Johnson & Johnson’s current ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.

Quick Ratio

Johnson & Johnson, quick ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Cash and cash equivalents 11,174  15,530  17,305  16,249  14,376  14,734  18,107  16,056  17,569  14,639  17,824  15,721  12,598  20,909  18,972  18,205  18,640  13,861  13,732  13,639  10,639  11,988 
Marketable securities 7,961  2,494  1,982  1,696  902  602  1,580  3,308  570  565  472  510  255  18,434  22,935  22,228  23,944  25,994  24,644  23,667  23,315  19,331 
Accounts receivable, trade, less allowances for doubtful accounts and credit losses 14,645  14,874  14,481  14,801  14,653  14,115  14,098  14,048  14,111  14,166  13,490  13,155  13,283  12,300  11,699  11,798  12,062  11,406  10,734  11,366  11,968  11,533 
Total quick assets 33,780  32,898  33,768  32,746  29,931  29,451  33,785  33,412  32,250  29,370  31,786  29,386  26,136  51,643  53,606  52,231  54,646  51,261  49,110  48,672  45,922  42,852 
 
Current liabilities 36,772  33,689  35,964  35,162  31,353  29,111  31,230  27,437  27,488  27,081  30,537  31,806  28,872  25,119  26,287  23,230  21,536  22,134  27,747  25,260  24,512  23,836 
Liquidity Ratio
Quick ratio1 0.92 0.98 0.94 0.93 0.95 1.01 1.08 1.22 1.17 1.08 1.04 0.92 0.91 2.06 2.04 2.25 2.54 2.32 1.77 1.93 1.87 1.80
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 0.93 0.83 0.88 0.93 0.98 0.94 1.03 1.00 0.94 1.04 1.67 2.02 2.13 2.01 3.31 0.94 0.92 0.88 1.04 1.10 1.60 1.45
AbbVie Inc. 0.58 2.88 2.91 0.92 0.64 0.78 0.78 0.95 0.55 0.90 0.89 1.11 0.98 1.24 1.14 1.42 1.41 1.25 1.21 1.57 1.12 1.10
Amgen Inc. 1.60 1.10 1.01 2.28 2.41 2.37 2.44 2.68 2.94 3.42 4.98 5.46 5.47 3.96 3.68 3.90 3.52 4.44 3.97 4.75 4.76 4.68
Biogen Inc. 2.00 1.39 1.43 1.57 1.70 2.07 1.83 2.19 1.79 2.67 1.78 1.62 1.49 1.57 1.94 2.44 2.16 1.91 1.93 2.84 1.57 1.98
Bristol-Myers Squibb Co. 1.26 1.38 1.26 3.63 3.61 1.64 1.39 1.31 1.18 1.29 1.37 1.38 1.36 1.37 1.35 1.24 1.30 1.22 1.07 1.30 1.23 1.44
Eli Lilly & Co. 0.68 0.64 0.68 0.66 0.67 0.65 1.20 1.36 0.96 0.87 0.91 0.94 0.92 0.78 0.98 1.06 1.00 0.98 1.04 1.01 1.01 0.95
Gilead Sciences Inc. 2.09 2.78 2.86 2.74 3.41 3.32 3.15 3.16 2.70 2.60 2.52 3.39 3.01 2.19 1.78 1.57 1.39 1.33 2.07 2.33 1.56 2.17
Illumina Inc. 3.28 3.61 6.00 5.99 5.95 3.28 2.23 2.20 2.39 2.35 3.43 3.65 3.32 2.98 2.75 3.05 3.09 3.63 2.90 3.17 2.59 2.42
Merck & Co. Inc. 0.84 0.66 0.78 0.80 0.75 0.88 0.72 0.95 0.82 0.86 0.83 0.97 1.03 1.13 1.24 1.31 1.26 1.13 1.04 1.05 1.02 1.09
Pfizer Inc. 0.98 0.60 0.50 0.50 0.71 0.72 0.84 0.94 0.72 0.76 0.93 0.95 0.88 0.94 0.84 0.70 0.94 0.99 1.07 1.08 1.62 1.81
Regeneron Pharmaceuticals Inc. 1.61 3.38 2.81 3.14 2.99 3.66 3.50 3.10 2.80 2.82 2.98 2.94 3.02 2.34 2.13 3.18 2.94 2.95 3.10 3.18 3.32 3.88
Vertex Pharmaceuticals Inc. 3.47 3.27 3.33 3.20 3.51 3.54 3.19 3.46 3.41 3.39 2.94 2.92 3.06 3.30 2.06 1.81 2.02 2.19 2.41 3.12 2.97 4.17
Zoetis Inc. 2.39 1.69 1.67 2.72 2.58 2.55 2.24 2.31 2.62 2.60 2.34 1.71 0.94 0.92 1.47 1.51 1.49 1.36 1.17 0.98 0.98 1.07

Based on: 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q2 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 33,780 ÷ 36,772 = 0.92

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Johnson & Johnson’s quick ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.

Cash Ratio

Johnson & Johnson, cash ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Cash and cash equivalents 11,174  15,530  17,305  16,249  14,376  14,734  18,107  16,056  17,569  14,639  17,824  15,721  12,598  20,909  18,972  18,205  18,640  13,861  13,732  13,639  10,639  11,988 
Marketable securities 7,961  2,494  1,982  1,696  902  602  1,580  3,308  570  565  472  510  255  18,434  22,935  22,228  23,944  25,994  24,644  23,667  23,315  19,331 
Total cash assets 19,135  18,024  19,287  17,945  15,278  15,336  19,687  19,364  18,139  15,204  18,296  16,231  12,853  39,343  41,907  40,433  42,584  39,855  38,376  37,306  33,954  31,319 
 
Current liabilities 36,772  33,689  35,964  35,162  31,353  29,111  31,230  27,437  27,488  27,081  30,537  31,806  28,872  25,119  26,287  23,230  21,536  22,134  27,747  25,260  24,512  23,836 
Liquidity Ratio
Cash ratio1 0.52 0.54 0.54 0.51 0.49 0.53 0.63 0.71 0.66 0.56 0.60 0.51 0.45 1.57 1.59 1.74 1.98 1.80 1.38 1.48 1.39 1.31
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.46 0.34 0.38 0.41 0.37 0.36 0.45 0.59 0.36 0.45 1.08 1.41 1.45 1.33 2.82 0.54 0.51 0.47 0.67 0.70 1.22 1.07
AbbVie Inc. 0.25 2.50 2.56 0.61 0.32 0.38 0.47 0.57 0.22 0.56 0.59 0.73 0.59 0.71 0.66 0.87 0.86 0.81 0.77 1.05 0.74 0.72
Amgen Inc. 1.09 0.68 0.69 1.94 2.05 2.07 2.17 2.41 2.62 3.07 4.62 5.05 5.02 3.65 3.40 3.60 3.23 4.08 3.62 4.34 4.35 4.28
Biogen Inc. 1.26 0.83 0.92 1.00 0.92 1.24 1.07 1.39 1.02 1.88 1.10 1.02 0.86 0.96 1.43 1.73 1.51 1.29 1.33 2.22 0.93 1.11
Bristol-Myers Squibb Co. 0.92 0.95 0.84 3.10 3.02 0.99 0.83 0.70 0.62 0.70 0.71 0.75 0.72 0.72 0.72 0.62 0.59 0.57 0.53 0.76 0.74 0.99
Eli Lilly & Co. 0.20 0.14 0.21 0.15 0.20 0.19 0.68 0.83 0.53 0.41 0.55 0.55 0.48 0.34 0.55 0.51 0.47 0.41 0.54 0.52 0.51 0.50
Gilead Sciences Inc. 1.79 2.34 2.50 2.39 3.03 2.97 2.84 2.81 2.38 2.25 2.19 2.96 2.48 1.70 1.29 1.11 0.84 0.76 1.48 1.68 0.96 1.52
Illumina Inc. 2.93 3.16 5.13 5.11 5.18 2.91 1.95 1.95 2.06 2.01 2.88 3.07 2.78 2.47 2.21 2.44 2.45 2.79 2.27 2.47 2.08 1.92
Merck & Co. Inc. 0.50 0.32 0.47 0.39 0.35 0.47 0.40 0.55 0.42 0.43 0.46 0.58 0.64 0.77 0.83 0.84 0.79 0.74 0.70 0.69 0.65 0.76
Pfizer Inc. 0.70 0.31 0.26 0.25 0.40 0.39 0.59 0.59 0.42 0.42 0.66 0.60 0.53 0.59 0.57 0.41 0.65 0.68 0.79 0.74 1.25 1.37
Regeneron Pharmaceuticals Inc. 0.85 1.95 1.53 1.63 1.56 2.14 1.95 1.55 1.26 1.28 1.24 1.21 1.23 1.00 0.84 1.47 1.10 0.92 1.29 1.22 1.00 1.38
Vertex Pharmaceuticals Inc. 3.03 2.72 2.85 2.88 3.14 3.14 2.83 3.08 2.98 2.99 2.59 2.55 2.67 2.88 1.81 1.56 1.72 1.86 2.06 2.68 2.72 3.91
Zoetis Inc. 1.85 1.13 1.07 1.74 1.66 1.66 1.39 1.39 1.61 1.65 1.43 1.13 0.40 0.36 0.65 0.63 0.63 0.58 0.65 0.36 0.35 0.41

Based on: 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q2 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 19,135 ÷ 36,772 = 0.52

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Johnson & Johnson’s cash ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.